Medical Devices Startups

Sully builds medical AI software for healthcare providers, including ambient documentation, scheduling, intake, and clinical decision support tools designed to reduce administrative burden and improve patient care efficiency.

12 investors

Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.

12 investors

Activ Surgical develops intraoperative surgical intelligence technology for surgeons, using AR, AI, machine learning, and sensing to display physiological structures and functions not visible to the naked eye. Its first product, ActivSight Intelligent Light, provides real-time dye-free perfusion and ICG imaging and is compatible with minimally invasive surgery systems.

11 investors

Aidoc develops an enterprise AI platform for hospitals that integrates clinical algorithms into existing workflows to prioritize patient findings and activate care teams across multiple departments. The platform serves healthcare systems and supports radiologists, clinicians, and other specialists in improving diagnostic efficiency and patient outcomes.

11 investors

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development. The company serves patients with cancer through novel drug candidates advancing in clinical trials.

11 investors

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors. Its lead focus is treating choroidal melanoma, a rare ocular cancer for which no first-line drug therapies currently exist.

11 investors

CatenaBio develops precision conjugation technology using native amino acids to enable biotherapeutic fusions of small molecules, nucleic acids, enzymes, and cells. The company partners with pharmaceutical firms to advance development of novel therapeutic modalities.

11 investors

Centaur.ai uses performance-based AI and collective intelligence methods to improve medical decision-making in skin lesion assessment for cancer detection. The company combines expert human judgment with AI algorithms weighted by demonstrated accuracy rather than credentials.

11 investors

Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies. The company serves cancer patients and their caregivers globally.

11 investors

FIGUR8 is an FDA-registered platform that provides objective, actionable insights for musculoskeletal health diagnosis and treatment. The platform originated from collaboration between MIT scientists, Massachusetts General Hospital, and the Boston Red Sox, and is now adapted for use across any point of care.

11 investors

Journey Clinical provides ketamine-assisted psychotherapy (KAP) for depression, anxiety, and PTSD, partnering patients with licensed therapists and medical teams while coordinating with major insurance providers.

11 investors

Juvena Therapeutics develops biologics derived from human secreted proteins to treat aging-related diseases, using AI-enabled drug discovery to identify tissue-restorative therapeutics for muscle and metabolic disorders.

11 investors

Leiters Health is an FDA-registered 503B outsourcing facility that produces sterile compounded preparations for hospitals, surgery centers, and ophthalmic use. Founded in 1926, it serves healthcare providers with compounded medications and offers an online ordering portal for registered customers.

11 investors

Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.

11 investors

Mytos develops automated manufacturing technology for regenerative medicines, specifically targeting the production of stem cell-derived therapies to make treatments for conditions like Parkinson's, blindness, and spinal cord injury accessible and affordable to patients.

11 investors

Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.

11 investors

Openwater develops an imaging platform using two optical modalities designed to diagnose and monitor diseases at the size and cost of a smartphone. The platform combines hardware, software, and open-source designs for use in clinical settings at hospitals, research institutions, and government programs worldwide, with trials spanning cancer, neurological disease, mental health, and metabolic conditions.

11 investors

Ossium Health develops cellular therapies and bioengineered products for clinical use, leveraging adult stem cell technologies and advanced cell processing platforms. The company operates as a clinical-stage biotech firm manufacturing and distributing cellular therapeutics for patients with organ and tissue diseases.

11 investors

Peptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.

11 investors

SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs. The company applies this "neuroimmune modulation" approach to autoimmune disease care.

11 investors

Subtle Medical develops deep learning software for medical imaging that enables faster and safer image acquisition on existing scanners for healthcare providers and imaging centers.

11 investors

Tubulis develops antibody-drug conjugates (ADCs) for cancer treatment, using proprietary conjugation platform technologies to create tumor-targeting therapeutics. The company operates in the biotech/oncology drug development industry, with sites in Munich, Cambridge (MA), and Lausanne.

11 investors

VeriSIM uses machine learning and computational simulation to accelerate drug development, replacing traditional trial-and-error experimentation with computational prediction to improve success rates and reduce animal testing. The company serves pharmaceutical partners and research institutions developing new medicines.

11 investors

Volumetric Biotechnologies, acquired by 3D Systems in 2021, develops bioprinting materials and vascularized human tissue constructs. The company operates a bioprinting facility in Houston, Texas focused on advancing technologies for tissue engineering and bioprinted constructs.

11 investors